Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.
Strategies to degrade steroid receptors and their alternative splicing isoforms are critical for disease management. Here we report that celastrol recruited the ubiquitin ligase UBE3A and degraded androgen receptor (AR), AR-v7, and glucocorticoid receptor (GR) to suppress prostate cancer development. UBE3A was not an optimal endogenous AR ubiquitin ligase in ... mice and patients, but celastrol promoted the interaction between UBE3A and AR. Multiple domains of AR, including the DNA binding domain (DBD), were implicated into the UBE3A-AR interaction. Sharing a conserved DBD, GR, AR-v7, and other steroid receptors were recognized and degraded by UBE3A after celastrol treatment. Thus, celastrol suppressed prostate cancer cell proliferation more potently than enzalutamide. Modifying the carboxyl group of celastrol improved its anti-tumor activity. Together, our findings revealed that celastrol might be a potential molecular glue to enhance the interaction between UBE3A and steroid receptors to degrade multiple steroid receptors and splicing isoforms in prostate cancer, paving a way for further drug optimization and disease treatment.
Mesh Terms:
Animals, DNA, Humans, Ligases, Male, Mice, Pentacyclic Triterpenes, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Protein Isoforms, Receptors, Androgen, Receptors, Glucocorticoid, Ubiquitin-Protein Ligases, Ubiquitins
Animals, DNA, Humans, Ligases, Male, Mice, Pentacyclic Triterpenes, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Protein Isoforms, Receptors, Androgen, Receptors, Glucocorticoid, Ubiquitin-Protein Ligases, Ubiquitins
Oncogene
Date: Oct. 01, 2022
PubMed ID: 36109631
View in: Pubmed Google Scholar
Download Curated Data For This Publication
239648
Switch View:
- Interactions 16